Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Weizmann researchers discover new neural mechanism underlying anxiety
Researchers at the Weizmann Institute of Science in Israel have revealed a previously unknown mechanism underlying anxiety.
Research & Development
-
13 Dec 2018
-
12 Dec 2018
Schrödinger, TB Alliance collaborate to advance tuberculosis drug discovery
Schrödinger and TB Alliance have entered into a three-year research collaboration to enhance the development of next-generation tuberculosis (TB) treatments by leveraging Schrödinger’s advanced computational platform for drug discovery.
-
12 Dec 2018
Versant Ventures launches new biotech firm Black Diamond Therapeutics
Versant Ventures, through a $20m Series A financing, has launched Black Diamond Therapeutics, a biotechnology company focused on developing a new type of precision medicine for cancer.
-
11 Dec 2018
e-therapeutics, Novo Nordisk enter into research collaboration deal
e-therapeutics has entered into a research collaboration with Danish drug manufacturer Novo Nordisk to discover biological mechanisms and therapies to treat type-2 diabetes.
-
06 Dec 2018
Mereo BioPharma, OncoMed agree to merge
UK-based clinical-stage biopharmaceutical firm Mereo BioPharma Group and oncology-focused clinical stage biopharmaceutical business OncoMed Pharmaceuticals have agreed to merge.
-
06 Dec 2018
Biopharmaceutical firm UCB to invest £1bn in UK for research and development
Global biopharmaceutical company UCB is investing around £1bn in the UK for research and development, supporting the country’s life sciences sector.
-
04 Dec 2018
DeepMind’s AlphaFold uses AI technology to predict protein shapes
Alphabet-owned DeepMind has claimed that research powered by artificial intelligence (AI) can help to predict the 3D structure of a protein on just its genetic sequence.
-
04 Dec 2018
TRIGR Therapeutics, ABL Bio sign license deal for bispecific antibody candidate
TRIGR Therapeutics has expanded bispecific immuno-oncology pipeline with exclusive global license of clinical stage, dual angiogenesis inhibitor from ABL Bio.
-
04 Dec 2018
GSK to buy oncology-focused biopharmaceutical firm Tesaro for $5.1bn
British drugmaker GlaxoSmithKline (GSK) has agreed to acquire US-based oncology-focused biopharmaceutical firm, Tesaro, for around £4bn ($5.1bn).
-
03 Dec 2018
Biopharmaceutical firm Aprea Therapeutics raises €50m in financing
Aprea Therapeutics, a biopharmaceutical company engaged in the discovery and development of anticancer compounds that reactivate the tumor suppressor protein, p53, has closed a €50m Series C financing round.